



Press release

ZEISS Medical Technology Nominated for Deutscher Zukunftspreis 2020

Improving medicine through robotics and multi-layered augmentation

Jena, 9 September 2020

ZEISS experts Dr.-Ing. Michelangelo Masini and Frank Seitzinger represent the ZEISS team and, together with Prof. Dr. med. Andreas Raabe from the Swiss Inselspital (University Hospital of Bern), have been nominated for the Deutscher Zukunftspreis 2020 (The Federal President's Award for Innovation and Technology). Their project: The Robotic Visualization System® – aka the KINEVO® 900 from ZEISS – which improves the efficiency and effectiveness of surgical procedures. With this award, German President Frank-Walter Steinmeier honors those scientists and their innovations that unlock scientific potential and create jobs.

Winners to be chosen on 25 November 2020

"We are delighted that a Carl Zeiss Meditec project has been nominated for this prestigious award," says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG and Member of the Board at Carl Zeiss AG. "This underscores our aspiration to create market-shaping innovations that improve patients' quality of life and help shape medical progress." ZEISS is the first-ever company to have two candidates nominated for the Deutscher Zukunftspreis since the accolade was first bestowed back in 1997. Alongside Carl Zeiss Meditec, a team from the ZEISS Semiconductor Manufacturing Technology segment has also made the shortlist.

The nomination of Prof. Dr. med. Andreas Raabe, Dr. Michelangelo Masini and Frank Seitzinger was officially announced today 20 at the German Museum in Munich. The path to the nomination required passing a multi-stage selection process and selection by a distinguished jury.

On 25 November 2020, the jury of the Federal President's Award for Innovation and Technology will decide which of the three nominated teams will take home the award.

Carl Zeiss Meditec's nominated project addresses demographic megatrends

We live in an aging society, which means ever more people will require medical treatment. Meanwhile, the population continues to grow – and an increasing number of people are gaining access to medical care. Healthcare systems across the world can only address this growing need if they become more efficient and more effective. Modern technologies like digitalization and artificial intelligence support healthcare providers as they administer these treatments. As does the ZEISS KINEVO 900, which is used in spinal and neurosurgery.

Comprising of more than 100 innovations and 180 patents, the system marries robotics, digital



visualization and modern assistance solutions. The development team worked with global clinical partners to define and develop a 3-in-1 system that unifies microscopic, exoscopic and endoscopic components. Many institutions have recognized the benefits of the Robotic Visualization System to make surgical treatment more effective and more efficient. Since the ZEISS KINEVO 900 was launched in early 2017, it has been granted regulatory approval in more than 100 countries. It is used in over 300,000 surgical procedures every year.

An innovation ready for the future

ZEISS KINEVO 900 is a future-ready platform that is constantly being optimized and expanded. First technologies are already available today. Sharing images via streaming technologies and using AI algorithms to recognize patterns are just a few of the features that were recently made available. "The continuous search for value-adding innovations is an important part of the ZEISS DNA," says Dirk Brunner, Head of the Microsurgery strategic business unit.

Contact for investors

Sebastian Frericks
Head of Investor Relations
Carl Zeiss Meditec AG
Phone: +49 (0)3641 220 116
Email: investors.meditec@zeiss.com

Press contact

Petra Rettenmaier
Head of Communications, Visualization and Microsurgical Workplaces
Carl Zeiss Meditec AG
Phone: +49 (0)3641 220 331
Email: press.med@zeiss.com

Brief Profile

Carl Zeiss Meditec AG (ISIN: DE0005313704) is one of the world's leading medical technology companies and is listed on the German MDAX and TecDax stock indices. The company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumables. In microsurgery, the company provides innovative visualization solutions. With approximately 3,232 employees worldwide, the company generated revenue totaling €1,459.3 m in fiscal year 2018/19 (ended 30 September 2019).

The company is headquartered in Jena, Germany, and has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the US, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India, and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world's leading companies in the optical and optoelectronic industries.

For more information, visit: www.zeiss.com/med

** Not all products, services or offers are approved or available in every market, and approved labeling and instructions may vary from one country to another. For country-specific product information, please see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development.*